Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiaPrecise in individuals at risk for Type 1 Diabetes
NCT05683990Phase 2Active, not recruiting
- Sponsor
- Diamyd Medical
- Start
- Jul 2024
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Diamyd in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Diamyd Medical. Primary endpoints: Occurrence of Adverse Events and Serious Adverse Events at 12 months, Number of Clinically Significant Abnormal Results from Physical examinations at 12 months and 1 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
Diamyd
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05683990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683990.